Read Larry Connors' blog – Short Term Trading Strategies
The adjustments are required, in accordance with the terms of the respective indentures governing the US$150 million Convertible Notes and US$276 million Convertible Notes, as a result of the Company's declaration of cash dividend of US$0.055 per ordinary share, equivalent to US$0.55 per ADS for the fiscal year ended March 31, 2009.
US$150 million Convertible Notes
Conversion rate of the US$150 million Convertible Notes is adjusted from 31.7378 American Depositary Shares ("ADSs") to 32.8322 ADSs for each US$1,000 original principal amount of the US$150 million Convertible Notes with reference to the closing market price of the Company's ADSs on September 29, 2009. The resulting conversion price for the US$150 million Convertible Notes is reduced from US$31.51 to US$30.46. Assuming full conversion of the US$150 million Convertible Notes, additional 1,641,600 ordinary shares, equivalent to 164,160 ADSs will be issued by the Company as a result of the adjustment to conversion rate. The adjustment became effective immediately prior to the opening of business on September 30, 2009.
US$276 million Convertible Notes
Conversion rate of the US$276 million Convertible Notes is adjusted from 17.0068 ADSs to 17.5899 ADSs for each US$1,000 original principal amount of the US$276 million Convertible Notes with reference to the average closing market price of the Company's ADSs over a 10 consecutive trading day period from September 14, 2009 to September 25, 2009. The resulting conversion price for the US$276 million Convertible Notes is reduced from US$58.80 to US$56.85. Assuming full conversion of the US$276 million Convertible Notes, additional 1,609,360 ordinary shares, equivalent to 160,936 ADSs will be issued by the Company as a result of the adjustment to conversion rate. The adjustment became effective immediately prior to the opening of business on September 28, 2009.
About China Medical Technologies, Inc.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .
For more information, please contact:
Winnie Yam
Tel: +852-2511-9808
Email: IR@chinameditech.com
SOURCE China Medical Technologies, Inc.
http://www.chinameditech.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.